TN2008 was selected as an effective SRSF1 inhibitor for HCC patients, demonstrating its ability to suppress LPS-induced TLR4 expression in BV-2 microglial cells.34 Our study revealed that TN2008 effectively inhibits SRSF1 protein function, exhibiting a binding energy of –5.1 kcal/mol (Fig. 5i). Here, TLR4 is linked to hepatocellular carcinoma.